These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 16432996)

  • 21. Sarcoidosis after interferon therapy for chronic active hepatitis C.
    Teragawa H; Hondo T; Takahashi K; Watanabe H; Ohe H; Hattori N; Watanabe Y; Amano H; Hino F; Ohbayashi M; Urushihara T; Yonehara S
    Intern Med; 1996 Jan; 35(1):19-23. PubMed ID: 8652926
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Interstitial pneumonitis during combination therapy with interferon-alpha and ribavirin in a patient with chronic Hepatitis C.
    Rothfuss KS; Bode JC
    Z Gastroenterol; 2002 Sep; 40(9):807-10. PubMed ID: 12215950
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Side effects of antiviral therapy in hepatitis C virus infection-sarcoidosis - case report.
    Teodor D; Teodor A; Grigore L; Jugănariu G; Dorobăţ CM; Miftode E; Azoicăi D
    Rev Med Chir Soc Med Nat Iasi; 2012; 116(4):1039-43. PubMed ID: 23700885
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Interferon-alpha 2b plus ribavirin in patients with chronic hepatitis C after liver transplantation: a randomized study.
    Samuel D; Bizollon T; Feray C; Roche B; Ahmed SN; Lemonnier C; Cohard M; Reynes M; Chevallier M; Ducerf C; Baulieux J; Geffner M; Albrecht JK; Bismuth H; Trepo C
    Gastroenterology; 2003 Mar; 124(3):642-50. PubMed ID: 12612903
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group.
    Davis GL; Esteban-Mur R; Rustgi V; Hoefs J; Gordon SC; Trepo C; Shiffman ML; Zeuzem S; Craxi A; Ling MH; Albrecht J
    N Engl J Med; 1998 Nov; 339(21):1493-9. PubMed ID: 9819447
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [A case of cardiac sarcoidosis occurring during combination therapy by IFN alpha and ribavirin for chronic hepatitis C].
    Iwashita M; Maeda T; Tagami A; Watanabe N; Takada J; Asano T; Hatakeyama H; Hayashi T; Nishiwaki S; Saito K
    Nihon Shokakibyo Gakkai Zasshi; 2010 Aug; 107(8):1319-27. PubMed ID: 20693757
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cutaneous sarcoidosis associated with pegylated interferon alfa and ribavirin therapy in a patient with chronic hepatitis C.
    Rogers CJ; Romagosa R; Vincek V
    J Am Acad Dermatol; 2004 Apr; 50(4):649-50. PubMed ID: 15034524
    [No Abstract]   [Full Text] [Related]  

  • 28. Safety of combination interferon alfa-2b/ribavirin therapy in chronic hepatitis C-relapsed and treatment-naive patients.
    Maddrey WC
    Semin Liver Dis; 1999; 19 Suppl 1():67-75. PubMed ID: 10349694
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Response to pegylated interferon alpha-2b and ribavirin in children with chronic hepatitis C.
    Baker RD; Dee D; Baker SS
    J Clin Gastroenterol; 2007 Jan; 41(1):111-4. PubMed ID: 17198073
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Sarcoidosis on the injection sites following treatment of interferon-alpha and ribavirin for hepatitis C.
    Chiang CH; Lai FJ
    J Formos Med Assoc; 2014 Dec; 113(12):981-2. PubMed ID: 25187070
    [No Abstract]   [Full Text] [Related]  

  • 31. Pleural effusion associated with pegylated interferon alpha and ribavirin treatment for chronic hepatitis C.
    Arora A; Vargas L; Kuzniar TJ
    J Hosp Med; 2009 Sep; 4(7):E45-6. PubMed ID: 19753589
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Sarcoidosis and chronic hepatitis C: a case report.
    Brjalin V; Salupere R; Tefanova V; Prikk K; Lapidus N; Jõeste E
    World J Gastroenterol; 2012 Oct; 18(40):5816-20. PubMed ID: 23155326
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Facial cosmetic filler injections as possible target for systemic sarcoidosis in patients treated with interferon for chronic hepatitis C: two cases.
    Descamps V; Landry J; Francès C; Marinho E; Ratziu V; Chosidow O
    Dermatology; 2008; 217(1):81-4. PubMed ID: 18446029
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of two PEG-interferon alpha-2b doses (1.0 or 1.5 microg/kg) combined with ribavirin in interferon-naïve patients with chronic hepatitis C and up to moderate fibrosis.
    Meyer-Wyss B; Rich P; Egger H; Helbling B; Müllhaupt B; Rammert C; Gonvers JJ; Oneta C; Criblez D; Rossi L; Borovicka J; Meyenberger C; Arn M; Renner EL;
    J Viral Hepat; 2006 Jul; 13(7):457-65. PubMed ID: 16792539
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Predictors of alpha-fetoprotein elevation in patients with chronic hepatitis C, but not hepatocellular carcinoma, and its normalization after pegylated interferon alfa 2a-ribavirin combination therapy.
    Chen TM; Huang PT; Tsai MH; Lin LF; Liu CC; Ho KS; Siauw CP; Chao PL; Tung JN
    J Gastroenterol Hepatol; 2007 May; 22(5):669-75. PubMed ID: 17444854
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A randomized trial of a 4- vs 12-week daily interferon dose regimen combined with ribavirin in treatment of patients with chronic hepatitis C.
    Sarin SK; Goyal A; Kumar S; Guptan RC; Hashmi AZ; Sakhuja P; Malhotra V
    Hepatobiliary Pancreat Dis Int; 2004 Feb; 3(1):42-8. PubMed ID: 14969836
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Interferon alfa-2b [correction of alpha-2b]and ribavirin for patients with chronic hepatitis C and normal ALT.
    Jacobson IM; Ahmed F; Russo MW; Lebovics E; Dieterich DT; Esposito SP; Bach N; Klion F; Tobias H; Antignano L; Brown RS; Gabbaizadeh D; Geders J; Levendoglu H
    Am J Gastroenterol; 2004 Sep; 99(9):1700-5. PubMed ID: 15330905
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Interferon-alpha-2b + ribavirin for the treatment of chronic hepatitis C in non-responders to interferon-alpha-monotherapy.
    Tromm A; Greving I; Griga T; Mankel K; Hüppe D
    Z Gastroenterol; 2000 Feb; 38(2):159-64. PubMed ID: 10721171
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A randomized controlled trial of pegylated interferon alpha-2a (40 KD) or interferon alpha-2a plus ribavirin and amantadine vs interferon alpha-2a and ribavirin in treatment-naïve patients with chronic hepatitis C.
    Mangia A; Ricci GL; Persico M; Minerva N; Carretta V; Bacca D; Cela M; Piattelli M; Annese M; Maio G; Conte D; Guadagnino V; Pazienza V; Festi D; Spirito F; Andriulli A
    J Viral Hepat; 2005 May; 12(3):292-9. PubMed ID: 15850470
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Viusid, a nutritional supplement, in combination with interferon alpha-2b and ribavirin in patients with chronic hepatitis C.
    Vilar Gomez E; Gra Oramas B; Soler E; Llanio Navarro R; Ruenes Domech C
    Liver Int; 2007 Mar; 27(2):247-59. PubMed ID: 17311621
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.